Table 1. Number (%) pts achieving CDCa
| Period 1 Treatmentb | ADA+MTX (N=515) | PBO+MTX (N=517) | |
|---|---|---|---|
| CDC Week 26 | 153 (29.7) | 83 (16.1) | |
| Period 2 Treatmentb | ADA+MTX (N=105) | PBO+MTX (N=112) | OL ADA+MTX (N=348) |
| CDC Week 26c | 62 (59.6) | 66 (58.9) | 16 (4.6) |
| CDC Week 52c | 63 (61.8) | 59 (54.1) | 61 (18.4) |
| CDC Week 78c | 61 (59.8) | 53 (48.6) | 82 (24.8) |
aDAS28<3.2+ ΔmTSS≤0.5+HAQ<0.5. bIntent-to-treat pts with at least one dose of study drug in period. c% based on # pts with a non-missing value at visit (MI). ADA, adalimumab; MTX, methotrexate; OL, open-label; PBO, placebo.